Merrion to start Orazol Phase III trial
Orazol is a tablet formulation of zoledronic acid, made possible by Merrion’s proprietary Gipet technology, for which there are issued US Orazol patents to 2027. Merrion said that
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
DelRx has proprietary platform drug delivery technology for transmucosal administration of large molecule drugs as a liquid dispersion, e.g., peptides like insulin, monoclonal antibodies, hormones, vaccines and other